Raymond James Financial
DNLI icon

Raymond James Financial’s Denali Therapeutics DNLI Stock Holding History

Raymond James Financial’s Portfolio DNLI Stock Details DNLI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.13M Buy
43,744
+9,361
+27% +$192K ﹤0.01% 3913
2026
Q1 		$660K Buy
34,383
+8,791
+34% +$175K ﹤0.01% 4151
2025
Q4 		$423K Buy
25,592
+266
+1% +$4.49K ﹤0.01% 4378
2025
Q3 		$368K Sell
25,326
-1,270
-5% -$18.2K ﹤0.01% 4295
2025
Q2 		$372K Buy
26,596
+662
+3% +$9.32K ﹤0.01% 4178
2025
Q1 		$353K Sell
25,934
-209
-0.8% -$4K ﹤0.01% 4121
2024
Q4 		$533K Buy
+26,143
New +$669K ﹤0.01% 3862

Other funds holding DNLI

T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Temasek Holdings
Temasek Holdings Singapore $37.3B AUM 12.6% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Raymond James Financial's DNLI Position: Q2 2026 in Review

Raymond James Financial increased its Denali Therapeutics (DNLI) stake by 27% in Q2 2026, buying an estimated $192K and bringing the position to 43,744 shares worth $1.13M. The position accounts for ﹤0.01% of the portfolio, ranked #3913.

Raymond James Financial first reported a position in DNLI in Q4 2024 and has held it in 7 quarters since. 292 funds tracked by Wall St. Rank hold DNLI as of Q2 2026.

  • Raymond James Financial held 43,744 shares of Denali Therapeutics worth $1.13M as of Q2 2026.
  • Raymond James Financial bought 9,361 Denali Therapeutics shares in Q2 2026, an estimated $192K.
  • Denali Therapeutics made up ﹤0.01% of Raymond James Financial's portfolio in Q2 2026, its #3913 holding.
  • Raymond James Financial first reported a position in Denali Therapeutics in Q4 2024 and has held it in 7 quarters since.
  • 292 funds tracked by Wall St. Rank held Denali Therapeutics as of Q2 2026.

Based on Raymond James Financial's 13F filing for Q2 2026, filed 14 Aug 2026.